PMID- 33864482
OWN - NLM
STAT- MEDLINE
DCOM- 20220110
LR  - 20220110
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Linking)
VI  - 279
IP  - 1
DP  - 2022 Jan
TI  - Comparison of treatment modalities for selected advanced laryngeal squamous cell 
      carcinoma.
PG  - 361-371
LID - 10.1007/s00405-021-06780-y [doi]
AB  - PURPOSE: The authors aimed to clarify the optimal treatment strategy and the 
      indication of different treatments in managing advanced laryngeal squamous cell 
      carcinoma (LSCC). METHODS: A total of 9700 patients with advanced (T3-4aN0-3M0) 
      LSCC who treated with (1) surgery alone, (2) surgery plus adjuvant radiation with 
      or without chemotherapy (aCRT/RT), or (3) definitive CRT/RT was retrieved from 
      the SEER database. The propensity score matching (PSM) was applied to balance 
      confounding factors. Kaplan-Meier method and Cox proportional hazards regression 
      were used to comparing the overall survival (OS) of patients. RESULTS: After 
      optimal matching, 907 patients were screened from each treatment cohort. 
      Kaplan-Meier and multivariate analyses presented that patients treated with 
      surgery plus aCRT/CT had significantly longer OS than those treated with either 
      surgery alone or CRT/RT, even after PSM. However, significant interactions were 
      tested in treatment effects in stratified analyses of the primary subsite, T 
      stage, N stage, and insurance status (P(Interaction) < 0.05 for all). 
      Specifically, surgery plus aCRT/CT significantly improved the OS of patients with 
      supraglottic, T4a, and N + tumors (P < 0.001 for all), while three treatment 
      modalities achieved equal OS rates for patients with glottic, T3, and N0 tumors 
      (P > 0.05 for all). Besides, supraglottic tumors presented a poorer prognosis 
      than glottic subsite. CONCLUSION: Current study suggests that surgery with 
      aCRT/RT is the preferred initial therapy for patients with T4a tumors, whereas 
      patients with T3 tumors could be treated with either surgery (followed by aCRT/RT 
      if it presents N +) or definitive CRT/RT for achieving laryngeal preservation. 
      More-intense treatment should be emphasized for advanced supraglottic cancer.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Wushouer, Aihemaiti
AU  - Wushouer A
AUID- ORCID: 0000-0001-8562-5269
AD  - Department of Otorhinolaryngology, NHC Key Laboratory of Otorhinolaryngology 
      (Shandong University), Qilu Hospital of Shandong University, Jinan, Shandong, 
      China.
FAU - Li, Wenming
AU  - Li W
AD  - Department of Otorhinolaryngology, NHC Key Laboratory of Otorhinolaryngology 
      (Shandong University), Qilu Hospital of Shandong University, Jinan, Shandong, 
      China.
FAU - Zhang, Minfa
AU  - Zhang M
AD  - Department of Otorhinolaryngology, NHC Key Laboratory of Otorhinolaryngology 
      (Shandong University), Qilu Hospital of Shandong University, Jinan, Shandong, 
      China.
FAU - Lei, Dapeng
AU  - Lei D
AUID- ORCID: 0000-0001-5637-3509
AD  - Department of Otorhinolaryngology, NHC Key Laboratory of Otorhinolaryngology 
      (Shandong University), Qilu Hospital of Shandong University, Jinan, Shandong, 
      China.
FAU - Pan, Xinliang
AU  - Pan X
AUID- ORCID: 0000-0002-1331-598X
AD  - Department of Otorhinolaryngology, NHC Key Laboratory of Otorhinolaryngology 
      (Shandong University), Qilu Hospital of Shandong University, Jinan, Shandong, 
      China. panxinlent@126.com.
LA  - eng
PT  - Journal Article
DEP - 20210417
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
SB  - IM
MH  - *Head and Neck Neoplasms
MH  - Humans
MH  - *Laryngeal Neoplasms/surgery
MH  - Laryngectomy
MH  - Neoplasm Staging
MH  - Retrospective Studies
MH  - Squamous Cell Carcinoma of Head and Neck/therapy
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma
OT  - Propensity score matching
OT  - SEER database
OT  - Treatment strategy
EDAT- 2021/04/18 06:00
MHDA- 2022/01/11 06:00
CRDT- 2021/04/17 12:05
PHST- 2021/01/18 00:00 [received]
PHST- 2021/03/22 00:00 [accepted]
PHST- 2021/04/18 06:00 [pubmed]
PHST- 2022/01/11 06:00 [medline]
PHST- 2021/04/17 12:05 [entrez]
AID - 10.1007/s00405-021-06780-y [pii]
AID - 10.1007/s00405-021-06780-y [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2022 Jan;279(1):361-371. doi: 
      10.1007/s00405-021-06780-y. Epub 2021 Apr 17.